Straits Times Index
3,313.48 +8.49 (+0.26%) S&P 500
5,303.27 +6.17 (+0.12%) Dow
40,003.59 +134.21 (+0.34%) Nasdaq
16,685.97 -12.35 (-0.07%) Bitcoin USD
66,749.65 -160.33 (-0.24%) CMC Crypto 200
1,361.32 -12.52 (-0.91%)
IO Biotech, Inc. (IOBT)
- GlobeNewswire
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with pembrolizumab still expected in Q3 2024; outcome of primary endpoint of progression free survival (PFS) is now projected to occur in first half of 2025Completed enrollment in Phase 2 basket trial IOB-022/KN-D38 and in first cohort of Phase 2 neoadjuvant/adjuvant bask
- GlobeNewswire
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024. A trial-in-progres
- GlobeNewswire
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
Marjan Shamsaei, PharmD, Newly Appointed as Senior Vice President, Commercial Development and Portfolio Lead Brings Deep Oncology Product Commercialization ExpertiseNEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-I
